Notably, recent studies of allogeneic CAR-T cells targeting CD70 have demonstrated promising safety and efficacy signals in renal cell carcinoma (RCC) (75, 76) and T-cell non-Hodgkin lymphoma (T-NHL) (77). The gene discussed is CD70; the disease is non-Hodgkin lymphoma.